Creative Planning Increases Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Creative Planning raised its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 18.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 25,925 shares of the company’s stock after purchasing an additional 3,979 shares during the quarter. Creative Planning’s holdings in Hims & Hers Health were worth $478,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Carnegie Investment Counsel purchased a new stake in Hims & Hers Health during the 3rd quarter valued at $5,531,000. CWM LLC boosted its position in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares during the period. Strategic Wealth Partners Ltd. boosted its position in Hims & Hers Health by 57.6% during the 3rd quarter. Strategic Wealth Partners Ltd. now owns 109,199 shares of the company’s stock valued at $2,011,000 after buying an additional 39,896 shares during the period. Diversified Trust Co purchased a new stake in Hims & Hers Health during the 3rd quarter valued at $233,000. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after purchasing an additional 328,142 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on HIMS. Bank of America upped their price objective on shares of Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Piper Sandler restated a “neutral” rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $487,789.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the transaction, the insider now directly owns 169,935 shares in the company, valued at $3,935,694.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 650,659 shares of company stock worth $11,712,198 over the last three months. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $23.44 on Thursday. The stock has a market capitalization of $5.03 billion, a PE ratio of 53.27 and a beta of 1.06. Hims & Hers Health, Inc. has a 52-week low of $6.58 and a 52-week high of $25.74. The company has a 50-day simple moving average of $18.22 and a two-hundred day simple moving average of $18.26.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the business posted ($0.04) earnings per share. The business’s revenue for the quarter was up 77.1% on a year-over-year basis. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.